{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:24:57Z","timestamp":1792002297242,"version":"4.4.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UM1 TR0045906"],"award-info":[{"award-number":["1UM1 TR0045906"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1UM1"],"award-info":[{"award-number":["1UM1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.annonc.2025.02.010","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T11:20:50Z","timestamp":1741087250000},"page":"507-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy assessment in phase I clinical trials: endpoints and challenges"],"prefix":"10.1016","volume":"36","author":[{"given":"M.A.","family":"Gouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Garrido-Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.annonc.2025.02.010_bib1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1634\/theoncologist.2017-0153","article-title":"The evolution of clinical trials in oncology: defining who benefits from new drugs using innovative study designs","volume":"22","author":"Goldberg","year":"2017","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.annonc.2025.02.010_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40473-018-0152-y","article-title":"Principles of designing a clinical trial: optimizing chances of trial success","volume":"5","author":"El-Hagrassy","year":"2018","journal-title":"Curr Behav Neurosci Rep"},{"issue":"12","key":"10.1016\/j.annonc.2025.02.010_bib3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-019-0262-9","article-title":"Phase I trials as valid therapeutic options for patients with cancer","volume":"16","author":"Adashek","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.02.010_bib4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.molonc.2014.07.025","article-title":"Early phase clinical trials to identify optimal dosing and safety","volume":"9","author":"Cook","year":"2015","journal-title":"Mol Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.02.010_bib5","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1200\/JOP.17.00058","article-title":"Examining trends in cost and clinical benefit of novel anticancer drugs over time","volume":"14","author":"Saluja","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"9","key":"10.1016\/j.annonc.2025.02.010_bib6","article-title":"Maximizing the value of phase III trials in immuno-oncology: a checklist from the Society for Immunotherapy of Cancer (SITC)","volume":"10","author":"Atkins","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2025.02.010_bib7","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","article-title":"Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016","volume":"178","author":"Moore","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"Spec Feature","key":"10.1016\/j.annonc.2025.02.010_bib8","first-page":"96","article-title":"Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.annonc.2025.02.010_bib9","series-title":"KEYTRUDA\u00ae (pembrolizumab) for injection, for intravenous use: FDA Packaging Insert","year":"2024"},{"issue":"4","key":"10.1016\/j.annonc.2025.02.010_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.seminoncol.2016.06.001","article-title":"Critical parameters in targeted drug development: the pharmacological audit trail","volume":"43","author":"Banerji","year":"2016","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.02.010_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1053\/j.seminoncol.2016.07.002","article-title":"Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development","volume":"43","author":"Parchment","year":"2016","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.02.010_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5306\/wjco.v11.i2.53","article-title":"Objective response rate assessment in oncology: current situation and future expectations","volume":"11","author":"Aykan","year":"2020","journal-title":"World J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.02.010_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2025.02.010_bib14","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.ejrad.2013.02.018","article-title":"Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals","volume":"82","author":"Zhao","year":"2013","journal-title":"Eur J Radiol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.02.010_bib15","article-title":"Intra-read analysis of radiologists in the setting of blinded independent central review of oncology studies","volume":"42","author":"Elbahnasawi","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2025.02.010_bib16","article-title":"Assessment of objective response rate (ORR) by investigator versus blinded independent central review in pivotal trials of drugs approved for solid tumor indications","volume":"39","author":"Zettler","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.02.010_bib17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jcph.1790","article-title":"Local investigators significantly overestimate overall response rates compared to blinded independent central reviews in phase 2 oncology trials","volume":"61","author":"Dello","year":"2021","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.annonc.2025.02.010_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx376.023","article-title":"1158P\u2014Is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?","volume":"28","author":"Ritchie","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.02.010_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.trecan.2020.01.005","article-title":"Hyperprogression and immunotherapy: fact, fiction, or alternative fact?","volume":"6","author":"Adashek","year":"2020","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2025.02.010_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.1839","article-title":"Hyperprogression in patients with cancer receiving immune checkpoint inhibitors","volume":"4","author":"Sehgal","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"31","key":"10.1016\/j.annonc.2025.02.010_bib21","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib22","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1038\/s41467-023-38837-3","article-title":"Towards evidence-based response criteria for cancer immunotherapy","volume":"14","author":"Garralda","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.annonc.2025.02.010_bib23","first-page":"284","article-title":"Evaluating for pseudoprogression in colorectal and pancreatic tumors treated with immunotherapy","volume":"41","author":"Parseghian","year":"2018","journal-title":"J\u00a0Immunother"},{"issue":"12","key":"10.1016\/j.annonc.2025.02.010_bib24","first-page":"1340","article-title":"Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?","volume":"11","author":"Sznol","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"issue":"11","key":"10.1016\/j.annonc.2025.02.010_bib25","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.annonc.2025.02.010_bib26","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2025.02.010_bib27","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.02.010_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju331","article-title":"Use and misuse of waterfall plots","volume":"106","author":"Shao","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.annonc.2025.02.010_bib29","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdw656","article-title":"3D waterfall plots: a better graphical representation of tumor response in oncology","volume":"28","author":"Castanon Alvarez","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.02.010_bib30","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2025.02.010_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials","volume":"13","author":"Pazdur","year":"2008","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.annonc.2025.02.010_bib32","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2011.34.6056","article-title":"Overall survival as the outcome for randomized clinical trials with effective subsequent therapies","volume":"29","author":"Korn","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s13063-023-07730-1","article-title":"How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review","volume":"24","author":"Royle","year":"2023","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.annonc.2025.02.010_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1758834010397692","article-title":"Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists","volume":"3","author":"Garcia","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.02.010_bib35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"34","key":"10.1016\/j.annonc.2025.02.010_bib36","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.annonc.2025.02.010_bib37","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1200\/JCO.23.01423","article-title":"Progression-free survival should not be used as a primary end point for registration of anticancer drugs","volume":"41","author":"Booth","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2025.02.010_bib38","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2025.02.010_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.8175","article-title":"Comparison of duration of response vs conventional response rates and progression-free survival as efficacy end points in simulated immuno-oncology clinical trials","volume":"4","author":"Hu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.annonc.2025.02.010_bib40","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jamaoncol.2020.4657","article-title":"Appropriate analysis of duration of response data in cancer trials","volume":"6","author":"McCaw","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2025.02.010_bib41","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/DDDT.S136988","article-title":"Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials","volume":"11","author":"Van Heertum","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"10.1016\/j.annonc.2025.02.010_bib42","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1007\/s00259-016-3365-x","article-title":"Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer","volume":"43","author":"Woff","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.annonc.2025.02.010_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138341","article-title":"The prognostic significance of metabolic response heterogeneity in metastatic colorectal cancer","volume":"10","author":"Hendlisz","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.annonc.2025.02.010_bib44","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.3802\/jgo.2022.33.e28","article-title":"Prognostic value of complete metabolic response on 18F-FDG-PET\/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer","volume":"33","author":"Chung","year":"2022","journal-title":"J\u00a0Gynecol Oncol"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.02.010_bib45","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.annonc.2025.02.010_bib46","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"Joo Hyun","year":"2016","journal-title":"Radiology"},{"issue":"19","key":"10.1016\/j.annonc.2025.02.010_bib47","doi-asserted-by":"crossref","first-page":"27848","DOI":"10.18632\/oncotarget.8425","article-title":"Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review","volume":"7","author":"Min","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib48","first-page":"1","article-title":"PERCIST in perspective","volume":"52","author":"Joo Hyun","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.annonc.2025.02.010_bib49","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00259-017-3703-7","article-title":"Comparison of FDG-PET\/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer","volume":"44","author":"Riedl","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.annonc.2025.02.010_bib50","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-016-3420-7","article-title":"Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer","volume":"43","author":"Shang","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"10.1016\/j.annonc.2025.02.010_bib51","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1158\/1078-0432.CCR-18-3964","article-title":"Alpha particle radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial","volume":"25","author":"Subbiah","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000439","article-title":"Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST","volume":"4","author":"Kairemo","year":"2019","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.annonc.2025.02.010_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101575","article-title":"Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors","volume":"8","author":"Kairemo","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib54","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature","volume":"46","author":"Aide","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.annonc.2025.02.010_bib55","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"(89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.annonc.2025.02.010_bib56","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-24-0897","article-title":"CTR-FAPI PET enables precision management of medullary thyroid carcinoma","volume":"15","author":"Kong","year":"2025","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.annonc.2025.02.010_bib57","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-24-1673","article-title":"Hidden in plain sight: clinical imaging of the tumor microenvironment with PET","volume":"15","author":"Witney","year":"2025","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.annonc.2025.02.010_bib58","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1586\/14737159.2015.1110021","article-title":"Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?","volume":"15","author":"Polivka","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"issue":"23","key":"10.1016\/j.annonc.2025.02.010_bib59","doi-asserted-by":"crossref","first-page":"7058","DOI":"10.1158\/1078-0432.CCR-19-1213","article-title":"Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC)","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.02.010_bib60","article-title":"Longitudinal monitoring of circulating tumor DNA to predict treatment outcomes in advanced cancers","volume":"6","author":"Gouda","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2025.02.010_bib61","article-title":"Monitoring of dynamic changes and clonal evolution in circulating tumor DNA from patients with IDH-mutated cholangiocarcinoma treated with isocitrate dehydrogenase inhibitors","volume":"6","author":"Lapin","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100357","article-title":"Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma","volume":"7","author":"Gouda","year":"2022","journal-title":"ESMO Open"},{"issue":"18","key":"10.1016\/j.annonc.2025.02.010_bib63","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2025.02.010_bib64","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/PO.20.00321","article-title":"Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy","volume":"5","author":"Thompson","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.02.010_bib65","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.annonc.2025.02.010_bib66","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","article-title":"Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.02.010_bib67","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","article-title":"Current and future clinical applications of ctDNA in immuno-oncology","volume":"82","author":"Stadler","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2025.02.010_bib68","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.02.010_bib69","unstructured":"FDA. Use of Circulating Tumor DNA for Early Stage Solid Tumor Drug Development: Guidance for Industry. Available at https:\/\/www.fda.gov\/media\/158072\/download. Accessed December 1, 2024."},{"key":"10.1016\/j.annonc.2025.02.010_bib70","unstructured":"ctMoniTR Project. ctDNA for Monitoring Treatment Response Project. Available at https:\/\/friendsofcancerresearch.org\/ctdna\/. Accessed December 1, 2024."},{"issue":"24","key":"10.1016\/j.annonc.2025.02.010_bib71","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.21.02615","article-title":"Using circulating tumor DNA in colorectal cancer: current and evolving practices","volume":"40","author":"Malla","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib72","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/med.21846","article-title":"A\u00a0review in radiomics: making personalized medicine a reality via routine imaging","volume":"42","author":"Guiot","year":"2022","journal-title":"Med Res Rev"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib73","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13014-022-02192-2","article-title":"A\u00a0review of radiomics and genomics applications in cancers: the way towards precision medicine","volume":"17","author":"Li","year":"2022","journal-title":"Radiat Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.02.010_bib74","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s11547-021-01436-7","article-title":"Delta radiomics: a systematic review","volume":"126","author":"Nardone","year":"2021","journal-title":"Radiol Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib75","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13244-023-01556-w","article-title":"Addressing challenges in radiomics research: systematic review and repository of open-access cancer imaging datasets","volume":"14","author":"Woznicki","year":"2023","journal-title":"Insights Imaging"},{"issue":"8","key":"10.1016\/j.annonc.2025.02.010_bib76","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41416-018-0245-0","article-title":"Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?","volume":"119","author":"Watson","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib77","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","article-title":"Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials","volume":"20","author":"Ferte","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.annonc.2025.02.010_bib78","first-page":"1079","article-title":"There are no bad anticancer agents, only bad clinical trial designs\u2014twenty-first Richard and Hinda Rosenthal Foundation Award Lecture","volume":"4","author":"Von Hoff","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.annonc.2025.02.010_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100072","article-title":"Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications","volume":"6","author":"Krebs","year":"2021","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.annonc.2025.02.010_bib80","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.3390\/cancers12123740","article-title":"Trabectedin plus radiotherapy for advanced soft-tissue sarcoma: experience in forty patients treated at a sarcoma reference center","volume":"12","author":"Hindi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.annonc.2025.02.010_bib81","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.3390\/cancers12113246","article-title":"Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer: an intra-patient comparative analysis","volume":"12","author":"Italiano","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.annonc.2025.02.010_bib82","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/2159-8290.CD-22-1377","article-title":"N-of-1 trials in cancer drug development","volume":"13","author":"Gouda","year":"2023","journal-title":"Cancer Discov"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.02.010_bib83","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1200\/JCO.2023.41.16_suppl.3086","article-title":"Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers","volume":"41","author":"Gouda","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.02.010_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101616","article-title":"Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens","volume":"8","author":"du Rusquec","year":"2023","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.annonc.2025.02.010_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103667","article-title":"TRAbectedin in adVanced rEtroperitoneal well differentiated\/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group","volume":"9","author":"Fabbroni","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib86","article-title":"Volumetric analysis: rethinking brain metastases response assessment","volume":"6","author":"Ocana-Tienda","year":"2024","journal-title":"Neurooncol Adv"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib87","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1038\/s41598-021-88426-x","article-title":"Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma","volume":"11","author":"Rexha","year":"2021","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.annonc.2025.02.010_bib88","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-secretase inhibitor for desmoid tumors","volume":"388","author":"Gounder","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2025.02.010_bib89","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A\u00a025-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2025.02.010_bib90","article-title":"Olaratumab\u2019s failure in soft tissue sarcoma","volume":"13","author":"Bou","year":"2021","journal-title":"Rare Tumors"},{"issue":"1","key":"10.1016\/j.annonc.2025.02.010_bib91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/cpt.2081","article-title":"Accelerated approval of anticancer drugs: lessons learned from the example of olaratumab","volume":"110","author":"Papachristos","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.annonc.2025.02.010_bib92","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.annonc.2025.02.010_bib93","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.02.010_bib94","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.annonc.2024.08.2337","article-title":"Optimizing tomorrow\u2019s drug development with project Optimus: precision dosing IS Precision Oncology","volume":"35","author":"Subbiah","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.02.010_bib95","doi-asserted-by":"crossref","first-page":"S895","DOI":"10.1016\/j.annonc.2023.09.2567","article-title":"Durable efficacy of zenocutuzumab, a HER2\u00a0\u00d7 HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)","volume":"34","author":"Schram","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.02.010_bib96","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2022.40.16_suppl.105","article-title":"Efficacy and safety of zenocutuzumab, a HER2\u00a0\u00d7 HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers","volume":"40","author":"Schram","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342500081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342500081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:26:35Z","timestamp":1778765195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342500081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S092375342500081X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.02.010","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy assessment in phase I clinical trials: endpoints and challenges","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}